AndhraNews.net
Home » Business News » 2014 » November » November 17, 2014

Daxor Corporation Announces Payment of a Dividend


November 17, 2014 - NEW YORK, NY

Daxor Corporation (NYSE MKT: DXR), an investment company with medical instrumentation and biotechnology operations, announced the payment of a dividend today.

The Board of Directors has unanimously approved payment of a dividend of $0.03 per share. The dividend will be paid on Friday, December 26th to shareholders of record on Monday, December 8th.

Daxor manufactures and markets the BVA-100 Blood Volume Analyzer which is used in conjunction with Volumex, Daxor's single use diagnostic kit. The BVA-100 provides key information that can be used to diagnose and treat various medical conditions including congestive heart failure, hypertension, anemia, blood loss during surgery, trauma, and septic shock (collapse of blood pressure). Sepsis is a very common condition in American hospitals. Ebola Hemorrhagic Fever is an example of a viral sepsis which is characterized by the destruction of red cells and damage to blood capillaries. Damage to the capillaries leads to critical proteins such as albumin and antibodies, along with plasma water being leaked into the surrounding tissue. This is a form of internal hemorrhage. Correct treatment is facilitated by direct measurement of blood volume which measures the red cell volume, plasma volume, and total blood volume. It is noteworthy that 8 of the 9 American patients diagnosed with Ebola Fever have survived. It was reported that the surviving patients were treated with blood plasma and red blood cell transfusions. Survival in septic patients depends on optimum replacement of intravascular fluids to restore a collapsing blood volume.

At the present time, physicians must treat these conditions by guessing whether or not they are due to volume expansions or contractions. The Blood Volume Analyzer allows for precise measurement of patients' total blood volume and red blood cell volume, which removes the guesswork. Appropriate therapies can then be employed to correct excesses or deficits in volume, leading to better outcomes for patients.

Daxor provides a unique frozen blood storage program for individuals through its Idant Laboratories subsidiary which allows someone to store their own blood for up to ten years. This is a major advantage over refrigerated blood which can only be stored for up to 42 days. It has been proven that if you need a transfusion, the safest blood to use is your own. The freezing and restoring of blood requires highly specialized technology. For more information regarding Daxor's Blood Volume Analyzer BVA-100, visit the Company's website at www.Daxor.com.

Daxor Contact Information:
David Frankel
Chief Financial Officer
212-330-8504
dfrankel@daxor.com
or
Diane Meegan
Investor Relations
212-330-8512
dmeegan@daxor.com

MarketWire

Comment on this story

Share